Preparation method and application of Tau protein nerve fiber based on chiral regulation

Tau protein racemates are incubated under specific conditions to form Tau protein nerve fibers, solving the problems of Tau protein self-assembly regulation and fiber preparation, and achieving batch preparation without auxiliary factors, which is a study of Alzheimer's disease Biotemplate fibers are provided.

CN119019526APending Publication Date: 2024-11-26CHONGQING INST OF GREEN & INTELLIGENT TECH CHINESE ACAD OF SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411136742.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The regulation of Tau protein self-assembly behavior, especially how racemates mediate Tau protein self-assembly, has not been reported, and the prior art is difficult to achieve batch preparation of Tau fibers without cofactors.

Method used

Tau protein nerve fibers were formed by incubating an equimolar mixture of the racemate L-Tau of Tau protein and its enantiomer D-Tau under specific conditions, and the reliability of the method was verified by AFM imaging, and the preparation conditions were optimized. To achieve batch preparation.

Benefits of technology

The tendency of Tau protein to self-assemble is significantly improved, and batch preparation of Tau fibers without other cofactors is achieved, providing biological template fibers without other cofactors for Alzheimer's disease research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019526A_ABST
    Figure CN119019526A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of Tau protein nerve fibers based on chiral regulation and control, and belongs to the technical field of Tau protein self-assembly. According to the method, the Tau fiber is prepared by using the Tau protein raceme in vitro, and then the reliability of the method is verified through AFM imaging. According to the method disclosed by the invention, other auxiliary factors do not need to be introduced, batch preparation of the Tau fiber can be realized under optimized fiber preparation conditions, and a biological template fiber without other auxiliary factors can be provided for researching the biotoxicity of Tau protein in the Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of Tau protein self-assembly, and in particular relates to a preparation method of Tau protein nerve fibers based on chirality regulation and application thereof. Background Art

[0002] Human Tau protein is encoded by the MAPT gene located on chromosome 17q21. Under pathological conditions, Tau protein can assemble to form neurofibrillary tangles. Neurofibrillary tangles formed by protein misfolding are one of the main pathological features of Alzheimer's disease (AD). The regulation of Tau protein self-assembly behavior is highly dependent on its sequence specificity and the complexity of the self-assembly microenvironment. The racemate is an equimolar mixture of an optically active chiral molecule and its enantiomer. At present, how the racemate mediates the self-assembly of Tau protein has not been reported. Summary of the invention

[0003] In order to solve the above technical problems, the present invention provides a method for preparing Tau protein nerve fibers based on chirality regulation and its application. The present invention first prepares Tau fibers in vitro using Tau protein racemate, and then verifies the reliability of the method by AFM imaging. The method of the present invention does not require the use of other auxiliary factors, and the fiber preparation conditions after optimization can realize the batch preparation of Tau fibers, which can provide a biological template fiber without other auxiliary factors for studying the biological toxicity of Tau protein in Alzheimer's disease.

[0004] In order to achieve the above object, the present invention adopts the following technical solutions:

[0005] The present invention provides a method for preparing Tau protein nerve fibers based on chirality regulation. The preparation method is carried out by placing a Tau protein racemate in a constant temperature bath at 35-39° C. and incubating at a rotation speed of 80-120 rpm for 1-3 days.

[0006] Preferably, the Tau protein is any one of the six subtypes of Tau protein or their polypeptide fragments, namely, 2N4R, 1N4R, 0N4R, 2N3R, 1N3R and 0N3R.

[0007] Any one of the Tau protein polypeptide fragments is formed by shearing, post-translational modification and other means of any one of the subtypes of Tau amino acid sequences.

[0008] More preferably, the Tau protein is a polypeptide fragment consisting of amino acids 391-426 of the human 2N4R subtype Tau protein, and the sequence is shown in SEQ ID NO.1.

[0009] Preferably, the Tau protein racemate is an equimolar mixture of L-Tau and its enantiomer D-Tau.

[0010] The L-Tau sequence is: EIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLA (SEQ ID NO.1), and its enantiomer D-Tau sequence is: eivykspvvsGdtsprhlsnvsstGsidmvdspqla (SEQ ID NO.2).

[0011] Note: In the writing of protein sequences, D-amino acids are generally marked with lowercase letters corresponding to L-amino acids. Since D-Tau and L-Tau are mutually chiral molecules and glycine does not have chiral enantiomers, it is still marked as G. In summary, the sequence of D-Tau is shown in SEQ ID NO.2.

[0012] Preferably, the Tau protein racemate is prepared by mixing 70 to 80 μL of a 35 to 45 μM L-Tau protein solution and a D-Tau protein solution in 140 to 160 μL of a buffer solution, and then vortex mixing for 0.5 to 1.5 min.

[0013] More preferably, the L-Tau protein solution and the D-Tau protein solution are both used in an amount of 75 μL, with a concentration of 40 μM, and the buffer solution is used in an amount of 150 μL. The vortex mixing is performed on a vortex machine for 1 minute.

[0014] Preferably, the pH value of the buffer solution is less than the isoelectric point of the Tau protein.

[0015] More preferably, the buffer solution is an ammonium acetate buffer solution with a concentration of 8 to 12 mM and a pH value of 3.5 to 4.5.

[0016] More preferably, the buffer solution is an ammonium acetate buffer solution with a concentration of 10 mM and a pH value of 4.0.

[0017] Preferably, the Tau protein nerve fibers are prepared by placing the Tau protein racemate in a constant temperature bath at 37° C. and incubating at a rotation speed of 100 rpm for 2 days.

[0018] The present invention also provides a Tau protein nerve fiber prepared by the preparation method.

[0019] The present invention also provides an application of the preparation method or the Tau protein nerve fiber in the preparation of Alzheimer's disease-related disease research products.

[0020] In the present invention, the specific parameters used in the preparation process of Tau protein nerve fibers can be adjusted according to actual conditions.

[0021] In the present invention, the samples before and after self-assembly can be characterized by imaging using AFM, and the AFM sample preparation method is as follows: the reaction solution before incubation and after incubation for 2 days are diluted 5 times with the buffer solution, and 50uL of the diluted solution is taken and dropped on the high-order pyrolytic graphite (HOPG). After 3 minutes, the excess sample solution is gently sucked away along one side of the HOPG with filter paper, and the HOPG surface is cleaned three times with Milli-Q water, and finally dried with nitrogen. After the above steps, the sample is adsorbed on the HOPG surface. The specific parameters can be adjusted according to the actual situation, and conventional AFM imaging substrates such as mica and silicon wafers can also be used for sample preparation.

[0022] In the present invention, the AFM imaging specifically refers to: imaging the sample adsorbed on the surface of HOPG or other substrates using the Tapping mode of AFM at room temperature.

[0023] Compared with the prior art, the present invention has the following technical effects:

[0024] (1) The present invention first prepared Tau fibers in vitro using Tau protein racemate, and then verified the reliability of this method through AFM imaging.

[0025] (2) Experimental data showed that only a small amount of fibers were produced when L-Tau and D-Tau were incubated alone, and D-Tau produced more fibers than L-Tau, indicating that D-Tau has a higher tendency to self-assemble. After 2 days of co-incubation of L-Tau + D-Tau (i.e., racemic form), the sample self-assembled from spheres to form Tau protein nerve fibers, and the number of fibers produced was far more than that of L-Tau / D-Tau when incubated alone, indicating that the racemic form of Tau protein, i.e., the use of chirality regulation, can significantly improve the self-assembly tendency of Tau.

[0026] (3) The method of the present invention does not require the use of other auxiliary factors. The optimized fiber preparation conditions can realize the batch preparation of Tau fibers, and can provide a biological template fiber without other auxiliary factors for studying the biological toxicity of Tau protein in Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The experimental process and effect diagram of preparing Tau protein nerve fibers by chirality regulation in Example 1 of the present invention;

[0028] Figure 2 This is an AFM image of L-Tau in Example 1 of the present invention after incubation for 2 days alone;

[0029] Figure 3 This is an AFM image of D-Tau in Example 1 of the present invention after incubation for 2 days alone;

[0030] Figure 4 This is an AFM image of L-Tau+D-Tau co-incubated for 0 days in Example 1 of the present invention;

[0031] Figure 5 This is an AFM image of L-Tau+D-Tau after co-incubation for 2 days in Example 1 of the present invention. DETAILED DESCRIPTION

[0032] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the method, steps or conditions of the present invention all belong to the scope of the present invention. The reagents and instruments used in the following examples can all be obtained commercially, and the methods used in the examples are consistent with the conventional methods unless otherwise specified.

[0033] The technical solution of the present invention is further described in detail below in conjunction with embodiments.

[0034] Example 1

[0035] This embodiment provides a method for preparing Tau protein nerve fibers based on chirality regulation: first take 0.5 mg of recombinant L-Tau and D-Tau powders in one tube each, add them to 3.3 mL of ammonium acetate buffer solution with a pH of 4.0 and a concentration of 10 mM, and vortex mix to obtain L-Tau protein solution and D-Tau protein solution with a concentration of 40 μM. Then, 75 μL of L-Tau protein solution with a concentration of 40 μM and 75 μL of D-Tau protein solution with a concentration of 40 μM are mixed in 150 μL of buffer solution (the buffer system is: pH 4.0, ammonium acetate buffer solution with a concentration of 10 mM). Subsequently, the mixed solution is placed on a vortex instrument and vortexed for 1 minute. Then, the solution after vortexing for 1 minute is placed in a constant temperature bath at 37°C and incubated at a speed of 100 rpm for 2 days. Subsequently, the reaction solution after incubation for 2 days was diluted 5 times with an ammonium acetate buffer solution with a pH of 4.0 and a concentration of 10mM, and 50uL of the diluted solution was aspirated and dropped on HOPG. After 3 minutes, the excess sample solution was gently aspirated along one side of HOPG with filter paper, and then the HOPG surface was washed three times with Milli-Q water and finally dried with nitrogen gas. After the above steps, the sample was adsorbed on the HOPG surface. The sample adsorbed on the HOPG surface was imaged using the Tapping mode of AFM at room temperature. At the same time, control groups were set up for L-Tau incubation for 2d alone, D-Tau incubation for 2d alone, and L-Tau + D-Tau co-incubation for 0d. The experimental process and effect diagram are shown in the figure. Figure 1 The AFM images of the different treatment groups are shown in Figure 2 to Figure 5 shown.

[0036] like Figure 2-Figure 5 As shown, the AFM imaging results can illustrate that the preparation method of Tau fibrillation provided in the present invention is reliable. Figure 2 and Figure 3 It can be seen that only a small amount of fibers were produced when L-Tau and D-Tau were incubated alone, and D-Tau produced more fibers than L-Tau, indicating that D-Tau has a higher tendency to self-assemble. Figure 4 and Figure 5 It can be seen that after 2 days of co-incubation of L-Tau+D-Tau (i.e., racemic form), the sample self-assembles from spheres to form Tau protein nerve fibers, and the number of fibers produced is far more than that when L-Tau / D-Tau is incubated alone, indicating that the racemic form of Tau protein, that is, the use of chiral regulation, can significantly improve the self-assembly tendency of Tau.

[0037] In summary, based on chirality regulation, Tau protein nerve fibers can be prepared in batches. This method can provide a biological template fiber without other auxiliary factors for studying the biological toxicity of Tau protein in Alzheimer's disease.

[0038] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A method for preparing Tau protein nerve fibers based on chirality regulation, It is characterized in that The preparation method is carried out by placing the Tau protein racemate in a constant temperature bath at 35-39° C. and incubating at a rotation speed of 80-120 rpm for 1-3 days.

2. The preparation method according to claim 1, It is characterized in that The Tau protein is any one of the six subtypes of Tau protein or their polypeptide fragments, namely, 2N4R, 1N4R, 0N4R, 2N3R, 1N3R and 0N3R.

3. The preparation method according to claim 2, It is characterized in that The Tau protein is a polypeptide fragment consisting of amino acids 391-426 on the human 2N4R subtype Tau protein, and the sequence is shown in SEQ ID NO.

1.

4. The preparation method according to claim 3, It is characterized in that The Tau protein racemate is an equimolar mixture of L-Tau and its enantiomer D-Tau.

5. The preparation method according to claim 4, It is characterized in that The Tau protein racemate is prepared by respectively placing 70 to 80 μL of L-Tau protein solution and D-Tau protein solution with a concentration of 35 to 45 μM in 140 to 160 μL of buffer solution, and then vortexing and mixing for 0.5 to 1.5 minutes.

6. The preparation method according to claim 5, It is characterized in that The pH value of the buffer solution is lower than the isoelectric point of the Tau protein.

7. The preparation method according to claim 6, It is characterized in that The buffer solution is an ammonium acetate buffer solution with a concentration of 8 to 12 mM and a pH value of 3.5 to 4.

5.

8. The preparation method according to claim 7, It is characterized in that The Tau protein nerve fibers are prepared by placing the Tau protein racemate in a 37° C. constant temperature bath and incubating at a rotation speed of 100 rpm for 2 days.

9. Tau protein nerve fibers prepared by the preparation method according to any one of claims 1 to 8.

10. Use of the preparation method according to any one of claims 1 to 8 or the Tau protein nerve fiber according to claim 9 in the preparation of products for research on Alzheimer's disease-related diseases.